Principal Investigator: Professor Erik Ingelsson
Department: Department of Medical Sciences
Uppsala University, Department of Medical Sciences, UCR/MTC, Dag Hammarskölds 14B, Uppsala 75237, SwedenTags: 13721, biomarkers, cardiovascular disease, causality, Mendelian randomization
1a: The overall goal of this project is to study the causal roles of the 36 biomarkers currently being assayed in UK Biobank for development of coronary heart disease, stroke and heart failure.
1b: Knowledge about causal relations of these 36 biomarkers with cardiovascular outcomes will give important insights regarding the etiological understanding of these diseases and accelerate development of new prevention strategies, including druggable targets. Hence, the proposed research does meet UK Biobank’s stated purpose via improving the prevention and treatment of heart disease and stroke.
1c: First, we will study associations of 36 circulating biomarkers representing different biological systems with incidence of coronary heart disease, stroke and heart failure.
Second, by combing data from the UK Biobank gene analyses with the biomarker data, we will perform genetic studies across the whole human genome for all 36 biomarkers to establish common genetic variation associated with respective biomarker.
Third, we will perform so called Mendelian randomization analyses to study whether the biomarkers are causally related to coronary heart disease, stroke and heart failure.
1d: Full cohort (n=502,650).
Studies of environmental and genetic risk factors for cardiovascular and diabetes outcomes, including their respective relations and interactions.
I am now interested in broadening the scope, both slightly with regards to outcomes and exposures. First, the original application mentioned coronary heart disease, ischemic and hemorrhagic stroke and heart failure as outcomes, but I would be interested in also looking at other cardiovascular events, such as atrial fibrillation, type 2 diabetes, QT-interval, sudden cardiac death, and imaging-based subclinical cardiovascular disease (such as atherosclerosis in carotids, subclinical measures of stroke and myocardial infarction, ejection fraction). Then, with regards to exposures, I would be interested in broadening the scope quite much into a more phenome-wide approach, studying a range of exposures that have been suggested to be associated with cardiovascular diseases in a Mendelian randomization framework to try to get a causality.
Last updated Sep 25, 2018